Homotaurine

CAS NO. 3687-18-1
Therapeutic Class: Nutraceuticals
Pharmacopoeia compliance: USP/Ph.Eur

Homotaurine had been found to bind to soluble amyloid beta and inhibit the formation of neurotoxic aggregates It has also shown anticonvulsant activities, reduction in skeletal muscle tonus and hypothermic activity.

Homotaurine has been reported as a GABA antagonist, as well as a GABA agonist.

One study showed that Homotaurine suppressed ethanol-stimulated dopamine release, as well as ethanol intake and preference in rats in a way similar to the N-acetyl derivative of Homotaurine Acamprosate. Acamprosate was approved by the FDA in 2004 to treat alcohol dependence.